Levonorgestrel-releasing intrauterine system	Oral norethisterone acetate	Median time to regression 	12117	12251	However, there was no significant difference between both groups regarding the median time to regression (3 months for each; p=0.697).
Levonorgestrel-releasing intrauterine system	Oral norethisterone acetate	Hysterectomy rate 	1208	1324	The hysterectomy rate during the follow-up period was significantly higher in the NET group (57.4% vs.22%, p<0.001).
Levonorgestrel-releasing intrauterine system	Oral norethisterone acetate	Median time to regression 	1120	1207	no significant difference was found regarding the median time to regression (3 months).
Levonorgestrel-releasing intrauterine system	Oral norethisterone acetate	Regression rate at 6 months	824	1110	A significantly higher regression rate was noted in the LNG-IUS group than in NET group at the 3rd, 6th and 12th month follow-up visits using intention-to-treat analysis (67.8% vs. 47.5%, relative risk [RR], 1.42; 79.7% vs. 60.7%, RR, 1.31; and 88.1% vs. 55.7%, RR, 1.58, respectively).
Levonorgestrel-releasing intrauterine system	Oral norethisterone acetate	Regression rate at 12 months	824	1110	A significantly higher regression rate was noted in the LNG-IUS group than in NET group at the 3rd, 6th and 12th month follow-up visits using intention-to-treat analysis (67.8% vs. 47.5%, relative risk [RR], 1.42; 79.7% vs. 60.7%, RR, 1.31; and 88.1% vs. 55.7%, RR, 1.58, respectively).
Levonorgestrel-releasing intrauterine system	Oral norethisterone acetate	Regression rate at 3 months	10978	11241	Following treatment, a significantly higher regression rate was noted in the LNG-IUS group than in NET group at the 3rd and the 6th month follow-up visits (67.8% vs. 47.5%, RR=1.42 [1.04-1.96], p=0.025; 79.7% vs. 60.7%, RR=1.31 [1.03-1.67], p=0.023, respectively)
Levonorgestrel-releasing intrauterine system	Oral norethisterone acetate	Regression rate at 3 months	824	1110	A significantly higher regression rate was noted in the LNG-IUS group than in NET group at the 3rd, 6th and 12th month follow-up visits using intention-to-treat analysis (67.8% vs. 47.5%, relative risk [RR], 1.42; 79.7% vs. 60.7%, RR, 1.31; and 88.1% vs. 55.7%, RR, 1.58, respectively).
